drugset / Trial / NCT00259363
Oxaliplatin in Rectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
* Phase I: To determine the maximum tolerated dose, and recommended dose of the proposed doses of oxaliplatin in this study * Phase II: To determine the treatment efficacy according to response rates from phase I.
Timeline
- Start
- 2002-10
- Primary completion
- 2006-06
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “Study cancelled because recruitment rate was too slow”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 60 mg/m2 | — |
| Background | fluorouracil | Small molecule | 225 mg/m2 | — |